NIMG-22. HIGH-GRADE GLIOMA OUTCOMES IN THE PHASE 1 BXQ-350 TRIAL OF CANCER-SELECTIVE SapC-DOPS NANOVESICLES. (5th November 2018)

• Record Type: Journal Article
• Authors: Puduvalli, Vinay; Villano, John; Wise-Draper, Trisha; Morris, John; Rixe, Olivier; Johnson, Angela; Giglio, Pierre; Otero, Jose
• Is Part Of: Neuro-oncology. Volume 20(2018)Supplement 6
• Page Start: vi180
• Page End: vi180
• Publication Date: 2018-11-05
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noy148.748
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: Saposin C-dioleylphosphatidylserine (SapC-DOPS) is a novel blood-brain barrier penetrant nanoliposomal agent that targets externalized phosphatidylserine overexpressed on tumor cell membranes. A recent Phase 1a BXQ-350 trial (NCT02859857) reported SapC-DOPS was well tolerated in both solid tumor and high-grade glioma (HGG) patients with potential for treating clinically challenging gliomas, including their diffuse infiltrative components. METHODS: We evaluated the HGG subset of the ongoing Phase 1 study of IV BXQ-350 administered on Days 1–5, 8, 10, 12, 15, 22 (cycle 1) and each 28 day cycles thereafter. MRI neuroimaging (e.g. Axial T1-post-contrast Ax SE T1 POST-FC and medically necessary views) at Days 29, 57, 113, and 171 (or withdrawal) were completed. RANO assessment, functional neurological deficits, ECOG Performance Status, and safety were assessed. RESULTS: The HGG patients (9/17) were dosed at 0.7 (N = 1), 1.1 (N = 1), 1.4 (N = 2), 1.8 (N = 2), or 2.4 (N = 3) mg/kg, with 8/9 completing a full cycle before withdrawal (7 due to progression, 1 voluntary withdrawal). BXQ-350 was not linked to dose limiting toxicities or severe adverse reactions. Functional neurological deficits and ECOG decline were proportional to radiological progression, with ECOG scores declining from a baseline 0–1 in 2/9 (22%) to 3. One patient completing 6 cycles (>12 months) of BXQ-350 therapy (0.7 mg/kg) exhibited stable disease, -7% lesion size, and no significant progressive functional neurological deficits. Three patients underwent surgery for progression while on treatment. CONCLUSIONS: BXQ-350 was well tolerated by GBM patients with promising best response apparent in neuroimaging, suggesting therapeutic benefit warranting further trials. Updates from the ongoing trial will be presented.